Transgene (France) Today
| TNG Stock | EUR 0.79 0.01 1.28% |
Performance0 of 100
| Odds Of DistressOver 87
|
Transgene is trading at 0.79 as of the 22nd of November 2024, a 1.28% up since the beginning of the trading day. The stock's open price was 0.78. Transgene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Transgene SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. The company has 100.2 M outstanding shares. More on Transgene SA
Moving together with Transgene Stock
Moving against Transgene Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Transgene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Transgene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Transgene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Transgene SA (TNG) is traded on Euronext Paris in France and employs 143 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 205.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Transgene's market, we take the total number of its shares issued and multiply it by Transgene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Transgene SA operates under Healthcare sector and is part of Biotechnology industry. The entity has 100.2 M outstanding shares.
Transgene SA has accumulated about 16.9 M in cash with (31.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check Transgene Probability Of Bankruptcy
Ownership AllocationTransgene SA shows a total of 100.2 Million outstanding shares. About 98.3 % of Transgene outstanding shares are held by general public with 1.7 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Transgene Ownership Details
Transgene SA Risk Profiles
Although Transgene's alpha and beta are two of the key measurements used to evaluate Transgene's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.34 | |||
| Standard Deviation | 3.48 | |||
| Variance | 12.14 | |||
| Risk Adjusted Performance | (0.07) |
Transgene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Transgene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Transgene Corporate Management
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maud MD | VP Officer | Profile | |
| Eric Quemeneur | Ex Officer | Profile | |
| Gaelle Stadtler | VP HR | Profile | |
| JeanPhilippe Del | VP CFO | Profile | |
| Hedi Brahim | CEO Director | Profile | |
| Elisabetta Castelli | Director Relations | Profile | |
| Lucie Larguier | Director IR | Profile |
Other Information on Investing in Transgene Stock
Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.